For example, certain mutations, such as HER2 amplification in breast cancer (25–27) or KRAS mutations in colorectal cancer (28, 29), help classify tumors into distinct subtypes, guiding treatment decisions and predicting prognosis. This evidence concerns the gene KRAS and breast carcinoma.